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Abstract
Background: Estrogens are known to regulate the proliferation of breast cancer cells and to
modify their phenotypic properties. Identification of estrogen-regulated genes in human breast
tumors is an essential step toward understanding the molecular mechanisms of estrogen action in
cancer. To this end we generated and compared the Serial Analysis of Gene Expression (SAGE)
profiles of 26 human breast carcinomas based on their estrogen receptor α  (ER) status. Thus,
producing a breast cancer SAGE database of almost 2.5 million tags, representing over 50,000
transcripts.
Results: We identified 520 transcripts differentially expressed between ERα -positive (+) and ERα -
negative (-) primary breast tumors (Fold change ≥  2; p < 0.05). Furthermore, we identified 220 high-
affinity Estrogen Responsive Elements (EREs) distributed on the promoter regions of 163 out of the
473 up-modulated genes in ERα  (+) breast tumors. In brief, we observed predominantly up-
regulation of cell growth related genes, DNA binding and transcription factor activity related genes
based on Gene Ontology (GO) biological functional annotation. GO terms over-representation
analysis showed a statistically significant enrichment of various transcript families including: metal
ion binding related transcripts (p = 0.011), calcium ion binding related transcripts (p = 0.033) and
steroid hormone receptor activity related transcripts (p = 0.031). SAGE data associated with ERα
status was compared with reported information from breast cancer DNA microarrays studies. A
significant proportion of ERα  associated gene expression changes was validated by this cross-
platform comparison. However, our SAGE study also identified novel sets of genes as highly
expressed in ERα  (+) invasive breast tumors not previously reported. These observations were
further validated in an independent set of human breast tumors by means of real time RT-PCR.
Conclusion: The integration of the breast cancer comparative transcriptome analysis based on
ERα  status coupled to the genome-wide identification of high-affinity EREs and GO over-
representation analysis, provide useful information for validation and discovery of signaling
networks related to estrogen response in this malignancy.
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Background
Estrogen plays essential roles in the development, growth
control and differentiation of the normal mammary
gland. However, it is well documented that endogenous
estrogens are powerful mitogens critical for the initiation
and progression of human breast and gynecological can-
cers [1]. This cell proliferation signal is mediated by the
estrogen receptors (ER), members of the nuclear receptor
family that function both as signal transducers and tran-
scription factors to modulate expression of target genes
[2]. There are two main subtypes of estrogen receptors:
ERα  and ERβ  that generally can form homo- and het-
erodimers before binding to DNA. Although the DNA
binding domains of these receptors are very similar, the
overall degree of homology is low [3].
Transcriptional regulation of target genes in response to
17β -estradiol (E2) is mediated by two main mechanisms.
In one, the E2-ER complex binds to a specific DNA
sequence called the estrogen response element (ERE), this
receptor-ligand DNA bounded complex interacts with co-
regulatory proteins, promoting chromatin remodeling
and bridging with the general gene transcription machin-
ery thus resulting in transcription initiation [4]. Alterna-
tively, the ligand-ER complex can interact with other
DNA-bound transcription factors that in turn bind DNA
sequences (e.g. via AP1, SP1 complexes) [5,6]. ERα  and
ERβ  have different affinities for different response ele-
ments and exhibit distinct transcriptional properties.
Additionally, E2 also exerts rapid, non-genomic effects
attributed to cell membrane-initiated signaling [7].
Approximately two-thirds of all breast cancers are ERα  (+)
at the time of diagnosis and expression of this receptor is
determinant of a tumor phenotype that is associated with
hormone-responsiveness. Patients with tumors that
express ERα  have a longer disease-free interval and overall
survival than patients with tumors that lack ERα  expres-
sion [8]. However, the association between ERα  expres-
sion and hormonal responsiveness is not perfect:
approximately 30% of ERα -positive tumors are not hor-
mone-responsive while 5–15% of ERα -negative tumors
respond to hormonal therapy [9]. The molecular basis for
the association between ERα  expression, hormonal
responsiveness and breast cancer prognosis remains
unclear.
Several studies have been carried out using cDNA and oli-
gonucleotide microarrays identifying breast cancer sub-
classes possessing distinct biological and clinical
properties [10-13]. Among the distinctions made to date,
the clearest separation was observed between ERα  (+) and
ERα  (-) tumors [10-15]. It has been suggested that there
are sets of genes expressed in association with ERα  that
could play an important role in determining the hor-
mone-responsive breast cancer phenotype [16]. ERα  is
obviously likely to be important for the E2 induced prolif-
erative response predominantly via the regulation of estra-
diol-responsive genes. Nevertheless, the expression of
additional subsets of genes not necessarily directly regu-
lated by estrogen may also be fundamental in defining the
breast cancer hormone-responsive phenotype.
To further elucidate the molecular basis of estrogen-
dependent breast carcinogenesis, we here report a com-
parative transcriptome profiling of invasive breast tumors
based on ERα  status obtained by SAGE. The SAGE method
provides a statistical description of the mRNA population
present in a cell without prior selection of the genes to be
studied, and this constitutes a major advantage [17]. The
breast cancer SAGE comparative analysis was combined
with promoter sequence analysis of genes of interest using
high-throughput methods of high-affinity ERE identifica-
tion. In order to have an even more comprehensive pic-
ture we also performed a cross-platform comparison
between SAGE and DNA microarray studies.
Results and discussion
Biomarkers of ERα  status in breast carcinomas
The primary goal of our study was to identify the most
commonly deregulated genes in invasive breast carcino-
mas related to ERα  status. To this end SAGE data was
obtained from a set of primary breast carcinomas. Thus, a
breast cancer SAGE database of almost 2.5 million tags
was analyzed, representing over 50,000 tag species. We
performed a comprehensive evaluation and comparison
of gene expression profiles using a recently developed
supervised method [18], to identify the most representa-
tive differentially expressed transcripts between tumors
groups, i.e. ERα  (+) vs. ERα  (-) breast tumors.
This statistical analysis revealed 520 genes differentially
expressed (Fold change ≥  2; p < 0.05) between ERα  (+)
and ERα  (-) primary breast carcinomas (see additional
data file 1). Among the 520 transcripts, 473 were up-mod-
ulated and 47 were down-modulated transcripts in ERα
(+) tumors.
The most commonly over-expressed transcripts in ERα  (+)
tumors were: trefoil factor 1 (TFF1/pS2), synaptotagmin-like
4  (SYTL4),  regulating synaptic membrane exocytosis 4
(RIMS4), dual specificity phosphatase 4 (DUSP4), chromo-
some 1 open reading frame 34 (C1orf34), necdin homolog
(NDN), n-acetyltransferase 1 (NAT1) and caspase recruit-
ment domain family 10 (CARD10) (Table 1 and additional
data file 1).
To validate novel ERα  associated genes detected by SAGE
not reported in other studies, we performed Real Time RT-
PCR analysis of representative transcripts in anBMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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Table 1: Most highly up-modulated transcripts in ERα  (+) breast carcinomas identified by SAGE.
Gene name Tag Locus Link Fold change (p value) Frequency#
Cell proliferation related
TFF1* (trefoil factor 1) CTGGCCCTCG 7031 51.4 (0.0016) 15/18 (83%)
DUSP4 (dual specificity phosphatase 4) CGGGCAGAAA 1846 14.7 (0.0016) 14/18 (78%)
NDN* (necdin homolog) ACCTTGCTGG 4692 13.3 (0.0026) 11/18 (61%)
HDGFRP3 (hepatoma-derived growth factor) TGTAAAGTTT 50810 9.8 (0.0019) 12/18 (67%)
TSPAN1* (tetraspan 1) GGAACTGTGA 10103 9.5 (0.0017) 15/18 (83%)
SEP6 (septin 6) TCAATTTTCA 23157 7.6 (0.0044) 12/18 (67%)
DHX34* (DEAH box polypeptide 34) GTTGCTCACT 9704 7.1 (0.0129) 9/18 (50%)
Apoptosis related
CARD10* (caspase recruitment domain family) AGAATGTACG 29775 11.1 (0.0030) 15/18 (83%)
Signal transduction related
SYTL4* (synaptotagmin-like 4) TATGTGTGCT 94121 28.0 (0.0003) 15/18 (83%)
ECM1* (extracellular matrix protein 1) ACTGCCCGCT 1893 10.1 (0.0175) 13/18 (72%)
LEPR* (leptin receptor) AAAGTTTGAG 3953 9.8 (0.0302) 10/18 (55%)
PTGES (prostaglandin E synthase) TGAGTCCCTG 9536 8.0 (0.0168) 8/18 (44%)
SCUBE2 (signal peptide, CUB domain EGF-like 2) TCAGCACAGT 57758 7.5 (0.0024) 14/18 (78%)
ADORA2A* (adenosine A2a receptor) TGCTGAGTAG 135 7.1 (0.0460) 11/18 (61%)
ITGBL1 (integrin beta-like 1) CATATTCACA 9358 7.1 (0.0159) 8/18 (44%)
Regulation of transcription related
ESR1 (estrogen receptor 1) AGCAGGTGCC 2099 9.8 (0.0000) 18/18 (100%)
TCEAL1 (transcriptional elongation factor A) AAAGATGTAC 9338 9.8 (0.0014) 13/18 (72%)
ZNF14 (zinc finger protein 14) TAAACAGCCC 7561 8.4 (0.0023) 13/18 (72%)
ZNF38* (zinc finger protein 38) CCAGCATTAC 7589 7.6 (0.0051) 10/18 (55%)
HIF1AN* (hypoxia-inducible factor 1α  subunit inhibitor) CCTGAGTGCG 55662 7.1 (0.0094) 10/18 (55%)
HOXC13 (homeo box C13) TTTTTAAAAT 3229 7.1 (0.0157) 9/18 (50%)
Cytoskeleton
MAPT (microtubule-associated protein tau) GTAGACTCGC 4137 9.8 (0.0085) 9/18 (50%)
MYLIP (myosin regulatory light chain interacting) TTTTCCACTC 29116 9.3 (0.0036) 11/18 (61%)
Metabolism and Miscelaneous
RIMS4 (regulating synaptic membrane exocytosis) TTGAAATTAA 140730 24.9 (0.0378) 8/18 (44%)
NAT1 (N-acetyltransferase 1) TATCTTCTGT 9 11.7 (0.0385) 15/18 (83%)
ATP6V1B1* (ATPase, H+ transporting) CCTCCCCCTC 525 10.7 (0.0111) 10/18 (55%)
JDP1 (J domain containing protein 1) TCTGTGAATT 56521 10.0 (0.0035) 12/18 (67%)
CHST11 (carbohydrate sulfotransferase 11) AACCTTCCTC 50515 9.8 (0.0009) 13/18 (72%)
CILP (nucleotide pyrophosphohydrolase) GTTTTGCCCA 8483 9.3 (0.0054) 14/18 (78%)
ABCA3 (ATP-binding cassette sub-family A) GTAGTCACCG 21 8.9 (0.0149) 10/18 (55%)
SEC14L2 GGAAGGCGGC 23541 8.7 (0.0487) 9/18 (50%)
ANXA9* (annexin A9) ACATCCGAGG 8416 8.4 (0.0145) 10/18 (55%)
KCTD3 (K channel tetramerisation domain 3) ATAATTAAAT 51133 8.4 (0.0001) 17/18 (94%)
SFRS7 (splicing factor) TAGCTAATAT 6432 8.0 (0.0031) 12/18 (67%)
SNRPA* (small nuclear ribonucleoprot. polypep. A) AAGATCTCCT 6626 7.6 (0.0009) 15/18 (83%)
NNMT (nicotinamide N-methyltransferase) CCTGCAATTC 4837 7.6 (0.0120) 10/18 (55%)
SLC1A4 (solute carrier family 1 member 4) GACTCACAGG 6509 7.6 (0.0254) 9/18 (50%)
TIPARP (TCDD-inducible polymerase) AAATGGCCAA 25976 7.6 (0.0051) 10/18 (55%)
SLC7A2 (solute carrier family 7 member 2) CACTGACAGC 6542 7.3 (0.0190) 11/18 (61%)
GA* (liver mitochondrial glutaminase) CTGCTGCTAC 27165 7.1 (0.0126) 9/18 (50%)
Function unknown
C1orf34 AGGATGTACA 22996 13.3 (0.0025) 14/18 (78%)
SMILE (hypothetical protein FLJ90492) TAGAGAGTTT 160418 11.1 (0.0004) 15/18 (83%)BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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RHBDL4 (rhomboid, veinlet-like 4) TTGTTTCTAA 162494 10.7 (0.0099) 9/18 (50%)
KIAA0882 GTCTCATTTC 23158 10.1 (0.0007) 18/18 (100%)
C20orf103* TTTAGTGATT 24141 9.3 (0.0277) 10/18 (55%)
FLJ33387 GCAGGGAGAG 161145 9.3 (0.0118) 10/18 (55%)
TRALPUSH GTTTCCAGAG 116931 8.9 (0.0458) 9/18 (50%)
KIAA0980* TGGTGCTTCC 22981 7.6 (0.0096) 11/18 (61%)
C10orf32 AGTCTGTTGT 119032 7.3 (0.0002) 15/18 (83%)
FLJ13611 TAATCACACT 80006 7.1 (0.0069) 10/18 (55%)
* Genes with known or putative high-affinity EREs mapping in the vicinity of the TSS.
# Transcripts tags changing > 2-fold when compared with the average expression of ER (-) tumors in at least 8 of 18 (44%) ERα  (+) invasive 
carcinomas SAGE libraries.
For the whole list of ERα  associated transcripts see additional data file 1.
Real time RT-PCR validation of nine over-expressed genes in 36 invasive breast carcinomas Figure 1
Real time RT-PCR validation of nine over-expressed genes in 36 invasive breast carcinomas. a) SCUBE2 (p = 
0.0001); b) SYTL4 (p = 0.0005); c) KIAA0882 (p = 0.0005); d) TSPAN1 (p = 0.001); e) CMYB (p = 0.002); f) CELSR2 (p = 0.011); 
g) NR4A1 (p = 0.029); h) ENO2 (p = 0.033); i) LGALS3BP (p = 0.079). Mean ± 2 Standard Error based on Log2 transformation 
of real time RT-PCR values of the assayed gene relative to 18S rRNA used as normalizing control.
Table 1: Most highly up-modulated transcripts in ERα  (+) breast carcinomas identified by SAGE. (Continued)BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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independent set of 36 invasive ductal breast carcinomas.
In agreement with our SAGE analysis, we detected statisti-
cal differences in the over-expression of 8 out of 9 evalu-
ated transcripts in ERα  (+) breast tumors including: signal
peptide CUB domain EGF-like 2 (SCUBE2) (p = 0.0001),
SYTL4 (p = 0.0005), KIAA0882 protein (p = 0.0005), tet-
raspan 1 (TSPAN1) (p = 0.001), myeloblastosis viral onco-
gene homolog (C-MYB) (p = 0.002), epidermal growth factor-
like 2 (CELSR2) (p = 0.011), nuclear receptor subfamily 4
(NR4A1) (p = 0.029), and enolase 2 (ENO2) (p = 0.033)
(Figure 1). A trend of borderline significance was detected
for the lectin galactoside-binding protein (LGALS3BP) (p =
0.079) transcript (Figure 1).
SCUBE2 (also known as EGF-like 2 or CEGP1) encodes a
secreted and cell-surface protein containing EGF and CUB
domains that defines a novel gene family [19]. The epider-
mal growth factor (EGF) motif is found in many
extracellular proteins that play an important role during
development, functioning as secreted growth factors,
transmembrane receptors, signaling molecules, and
important components of the extracellular matrix. The
CUB domain is found in several proteins implicated in the
regulation of extracellular process such as cell-cell com-
munication and adhesion [20]. Expression of SCUBE2 has
been detected in vascular endothelium and may play
important roles in development, inflammation and per-
haps carcinogenesis [19].
The CELSR2 gene (also known EGFL2) encodes a protein
member of the nonclassic-type cadherins (flamingo sub-
family). These 7-pass transmembrane proteins have nine
cadherin domains, seven-epidermal growth factor-like
repeats and two laminin A G-type repeats [21]. It is postu-
lated that these proteins are receptors involved in cell
adhesion and receptor-ligand interactions [21] playing a
role in developmental processes and cell growth/ mainte-
nance in epithelial and neuronal cells [22,23].
SYTL4 (also known as granuphilin-a or SLP4) contains an
N-terminal Slp homology domain (SHD) than can specif-
ically and directly bind the GTP-bound form of Rab27A, a
small GTP-binding protein involved in granule exocytosis
in cytotoxic T lymphocytes [24]. We determined that over-
expression of SYTL4 is associated with ERα  (+) tumors
(Figure 1b). However, the potential role of this gene in
breast carcinogenesis remains unknown.
ENO2 (also known as NSE/neuron-specific gamma enolase)
encodes one of three enolase isoenzymes found in mam-
mals. This isoenzyme was described to be expressed in
cells of neuronal origin. Interestingly, in a recent report
Hao et al. (2004) showed high expression of ENO2 tran-
scripts in breast cancer lymph node metastases when com-
pared with primary breast tumors [25].
The TSPAN1 gene (also known as tetraspanin or NET1)
encodes a cell-surface protein member of the transmem-
brane 4 superfamily (TM4SF), involved in the regulation
of cell development, activation, growth and motility. A
number of tetraspanins were described as tumor-specific
antigens, and it was suggested that the function of some
TM4SF proteins may be particularly relevant to tumor cell
metastasis [26]. Sugiura and Berditchevski (1999)
observed that TSPAN1 protein complexes may control the
invasive migration of tumor cells and contribute to ECM-
induced production of MMP2 in breast cancer cell line
[27].
NR4A1, a nuclear receptor subfamily 4, group A gene (also
known as steroid receptor TR3 or  NUR77) encodes an
orphan member of the steroid-thyroid hormone-retinoid
receptor superfamily whose members mainly act as tran-
scriptional factors to positively or negatively regulate gene
expression and play roles in regulating growth and apop-
tosis [28,29]. A role for NR4A1 in cell proliferation has
been previously reported. It was shown that its expression
is rapidly induced by various mitogenic stimuli such as:
serum growth factor, epidermal growth factor and fibrob-
last growth factor [28].
Taken together, the genes that we identified and validated
appear to be involved in signaling pathways related to cell
proliferation, invasion and metastatic processes, but their
exact role in breast carcinogenesis remains to be
elucidated.
Gene Ontology analysis
Classification of genes based on Gene Ontology (GO)
terms is a powerful bioinformatics tool suited for the anal-
ysis of DNA microarray and SAGE data. Analysis of GO
annotation allows one to identify families of genes that
may play significant roles related to specific molecular or
biological processes in expression profiles [30]. We used
the Expression Analysis Systematic Explorer software (EASE)
[31] to annotate the 520 deregulated genes according to
the information provided by the GO Consortium [30].
The GO database provided annotation for 80% (419 out
of 520) of the genes identified by SAGE. Results of this
analysis are shown in Figure 2 and in detail in additional
data file 2.
We observed that 31% of ERα  associated transcripts are
involved in biological processes related to cell growth and/
or maintenance, 21% are related to cell communication, and
16% are related to regulation of transcription. Approxi-
mately 16% of these deregulated genes are related to
molecular functions associated with DNA binding and
more specifically with transcription factor activity (10%)
(Figure 2). Interestingly, using the enrichment GO terms
analysis, we identified statistical significant over-represen-BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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tation of specific groups of proteins including: metal ion
binding proteins (54 hits out of 419 annotated genes; p =
0.011), calcium ion binding proteins (27 hits out of 419; p =
0.032) and steroid hormone receptor activity related proteins
(6 hits out of 419; p = 0.031) (additional data file 2). The
GO cluster related to steroid hormone receptor activity pro-
teins includes: estrogen receptor 1 (ESR1, i.e. ERα ), androgen
receptor  (AR),  hydroxysteroid 17-β  dehydrogenase 4
(HSD17β 4), glucocorticoid receptor (NR3C1), oxysterol bind-
ing protein (OSBP), and retinoic acid receptor α  (RARA). The
observation of functionally related groups of genes identi-
fied in the SAGE dataset via GO over representation anal-
ysis allows the identification of distinct biological
pathways directly or indirectly associated to estrogen
response related processes and provides the basis for
future mechanistic studies.
Identification of high-affinity Estrogen Response Elements
We used a recently reported genome-wide high-affinity
ERE database [32] to identify putative EREs in the pro-
moter regions of the SAGE-identified 473 up-modulated
genes in ERα  (+) breast tumors. We identified 220 EREs
distributed on 163 out of the 473 genes (35%) (see addi-
tional data file 3). Seventy-two percent of these genes con-
tain one high affinity ERE (117 out of 163) and 28% of
them contain two or more EREs in proximity to the tran-
scriptional start sites (TSS) (46 out of 163) (Figure 3a).
These EREs can be located in both coding and non-coding
sequences such as was described by Bourdeau et al. [32].
The observed frequency of these elements in our study
was 220 EREs in 3260 kb (considering a DNA window of
20 kb for each one of the 163 up-modulated genes with
EREs). Compared with the expected frequency from ran-
dom distribution of high-affinity EREs found in the
genome (732 EREs in 3,069334 kb 0.8 ERE in 3260 kb)
(see material and methods) [32], the number of
individual EREs was 270 fold higher than expected by
chance (p < 0.00001).
Fifty percent (110 out of 220) of the detected EREs
mapped within a 10 kb region 5' of the TSS, while the rest
mapped to 3' regions (Figure 3b). Approximately 68% of
EREs mapped within the region between -5 to +5 kb from
the TSS; in agreement with those observations of Bour-
deau et al. [32]. However, it remains to be determined
whether distantly located EREs (e.g. -10 kb from the TSS)
are functional E2-ER binding sites related to transcrip-
tional activation.
Of the validated transcripts previously discussed (Figure
1), we detected high-affinity EREs on the upstream or
downstream regions related to the TSS of SYTL4 (-8384 bp
from the TSS: tggacatcatgacct), TSPAN1  (+974 bp and
+9384 bp from the TSS: tggtctgaatgaccc and aggtcatttccacct
respectively), CELSR2 (+173 bp and +3607 bp from the
TSS: tgctcagggtgaccc and aggtcaccatgaccg respectively),
and  NR4A1  (-3478 bp and +4217 bp from the TSS:
tgttcactctgacct).
It is interesting to note that we were unable to identify
high-affinity EREs on the majority of deregulated genes
(65%) associated with a positive ER α  status. The possibil-
ity exists that many of these genes are transcriptionally
regulated by non-ERE mediated mechanisms such as
those involving ER binding to the AP1 or SP1 transcrip-
tion factors [33]. The AP1 transcription factor is a het-
erodimer formed by Jun and Fos family member proteins
that binds to the phorbol diester (TPA) response element
as well as to the AP1 consensus DNA sequence. In this
pathway, ER plays a co-activator role for AP1 [6]. The ER/
AP-1 complex can confer estrogen responsiveness to
additional subset of genes found in our dataset such as:
ovalbumin  (Fold change: 3; p = 0.033) and c-fos  (Fold
change: 2.1; p = 0.033); two transcripts detected as over-
expressed in ERα  (+) breast tumors by SAGE (additional
data file 1). Similarly the ER/SP1 complex confers estro-
gen responsiveness to genes such as: retinoic acid receptor α
(RARA) (Fold change: 6.7; p = 0.038), vascular endothelial
growth factor (VEGFC) (Fold change: 2.6; p = 0.037), insu-
GO classification of the ERα  associated genes identified by  SAGE Figure 2
GO classification of the ERα  associated genes identi-
fied by SAGE. Percent of coverage representing the per-
centage of genes annotated with a specific GO term related 
to Biological Processes (blue bars) and Molecular Function 
(yellow bars).BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
Page 7 of 13
(page number not for citation purposes)
lin-like growth factor binding protein-4 (IGFBP4) (Fold
change: 2; p = 0.01) and heat shock protein 27 (HSPB1)
(Fold change: 2; p = 0.045); four transcripts detected as
over-expressed in ERα  (+) tumors in our study (additional
data file 1).
An additional pathway of transcription regulation by
estrogen involves the ER-related receptors (ERR), nuclear
orphan receptors with significant homology to ERs, which
do not bind estrogen and have unknown physiological
ligands. ERRs are known to bind to the steroidogenic fac-
tor 1 response element (SFRE) and also bind to classic
EREs, by means of which they exert constitutive transcrip-
tional activity [34]. We detected over-expression of the
nuclear orphan receptor NR4A1  by SAGE and subse-
quently validated this observation by real time RT-PCR
(Figure 1g). Interestingly, and as previously mentioned,
the genomic region 5' and 3' to the TSS of NR4A1 contain
high-affinity EREs. Interaction between ERs and ERRs has
been observed in the transcriptional regulation of certain
genes such as the human breast cancer related gene TFF1/
pS2, the promoter of which is not only activated by ERs
but also by ERRs [35].
As described, ERα  can mediate estrogenic response
through multiple genomic and non-genomic mecha-
nisms, many of which affect proteins and pathways not
necessarily directly or exclusively associated with ERα .
Thus it is worth stressing that it will the totality of deregu-
lated proteins the ones that ultimately define the pheno-
type of ERα  (+) breast carcinomas regardless of whether a
"direct association" with ER transcriptional regulation
exists or not.
In vivo versus in vitro estrogen induced global gene 
expression findings
The SAGE profiles for E2-responsive genes in MCF-7 cell
line, previously reported by us [36], was compared with
the ER status genes expression profile found in primary
breast carcinomas. Briefly, we detected 199 transcripts dif-
ferentially expressed (p < 0.01) in MCF-7 treated cells, 124
were up-regulated and 75 were down-regulated
High-affinity EREs in ERα  (+) up-modulated genes (n = 163) Figure 3
High-affinity EREs in ERα  (+) up-modulated genes (n = 163). a) Percentage of genes according to number of EREs. b) 
Distribution of EREs in 5' (blue bars) and 3' (aquamarine bars) regions relative to the TSS (-10 to + 5 kb). Each bar represents 
an interval width of 500 bp.BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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transcripts. Basically and as reported Charpentier et al, we
observed a general up-regulation cell cycle progression-
related genes including: CCT2, CCND1, PES1, RAN/TC4,
CALM1,  CALM2; and tumor-associated genes such as:
RFP, D52L1, TFF1/PS2, CAV1, and NDKA among others
[36]. These together could contribute to the stimulation of
proliferation and the suppression of apoptosis by E2-ER
transcriptional regulation.
By comparing the in vitro (199 differentially expressed
transcripts) and in vivo (520 differentially expressed tran-
scripts) gene expression profiles, to our surprise we detect
that only few transcripts: TFF1, CCND1, H19, SREBF1 and
WWP1  behaved similarly (i.e. up-regulation) in both
studies. This is similar to observations made previously by
Meltzer and co-workers whom showed that the majority
of genes regulated in cell culture do not predict ER status
in breast carcinomas [11,37]. This result suggests that the
estrogen-responsive pathways affected in vitro represent
only a minor portion of the global gene expression pro-
files characteristic of ERα  (+) breast tumors. This maybe in
great part the result of the heterogenous nature of bulk
tumor tissue but in addition, the in vitro response of a sin-
gle cell line to E2, in this particular case the widely used
MCF-7 cells, may not faithfully reproduce the physiologi-
cal effects of ER signaling in vivo.
Cross-platform gene expression profiling comparison
In order to identify and validate the most reliable set of
genes able to discriminate breast carcinomas based on
their ERα  status, we performed a cross-platform compari-
son between the described SAGE dataset with two previ-
ously reported breast cancer studies based on DNA
microarray methods [12,13]. van't Veer et al. [12] reported
the gene expression profile of 97 primary breast tumors
based on oligonucleotide microarrays containing 24,479
elements (Agilent Technologies, Palo Alto, CA, USA). In
another study, Sotiriou et al. [13] reported the gene
expression profile of 99 primary breast tumors using a
cDNA microarray containing 7650 elements. Only files
containing differentially expressed genes associated to
ERα  status tumors from both microarrays studies were
obtained for cross-platform comparison (see material and
methods).
Among the three platforms, a total of 1686 transcripts
were identified as over-expressed in ERα  (+) breast
tumors. One hundred and eighty-three genes were identi-
fied by more than one method (Figure 4; additional data
file 4). Eleven of these 183 genes were identified by all
three methods displaying over-expression in ERα  (+)
breast carcinomas: estrogen receptor 1 (ESR1), GATA-bind-
ing protein 3 (GATA3), mucin 1 (MUC1), v-myb-myeloblast-
osis viral oncogene homolog (C-MYB) , X-box-binding protein
1 (XBP1), hydroxysteroid 17-β  dehydrogenase 4 (HSD17B4),
BTG family member 2 (BTG2), transforming growth factor β -
3 (TGFB3), member RAS oncogene family (RAB31), START
domain containing 10 (STARD10), and KIAA0089 (Table
2).
One hundred and fourteen genes were identified as over-
expressed by oligonucleotide microarrays [12] and SAGE
in ERα  (+) tumors, representing a non-random significant
number of overlapping genes based on normal approxi-
mation to the binomial distribution (p < 0.001) (Figure 4
and Table 2). Sixty-six genes were identified as over-
expressed in ERα  (+) tumors by both DNA microarrays
platforms (p < 0.01). The set of 25 genes overlapping
between cDNA microarrays [13] and SAGE were not sta-
tistical significant (p > 0.05).
Interestingly, we found a higher number of overlapping
genes between the oligonucleotide microarray and SAGE
platforms (114 genes), while only 66 genes were observed
overlapping when comparing both microarray platforms.
It is worth noting that 96% of the 470 genes (Figure 4)
identified as overexpressed by the cDNA microarray
method [13] were included within the total set of ele-
ments in the oligonucleotide microarray platform [12]. In
Cross-platform comparisons of the up-modulated transcripts  in ERα  (+) breast carcinomas Figure 4
Cross-platform comparisons of the up-modulated 
transcripts in ERα  (+) breast carcinomas. One hundred 
and eighty-three genes were identified by more than one 
study, eleven of which were commonly identified across the 
three platforms. a) Comparison between SAGE and oligonu-
cleotide microarray platforms [12] showing a highly signifi-
cant number of overlapping genes (p < 0.001) (see table 2). 
b) Comparison between SAGE and cDNA microarray plat-
forms [13] (p > 0.05). c) Statistically significant number of 
overlapping genes identified by both DNA microarrays plat-
forms (p < 0.01).BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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Table 2: Transcripts identified as over-expressed in ERα  (+) breast cancers commonly detected by cross-platforms comparison (SAGE 
and oligonucleotide microarrays).
Gene name Locus Link ID Fold change Frequency Gene name Locus Link Fold change Frequency#
TFF1* 7031 51.4 15/18 (83%) SULF2 55959 2.9 11/18 (61%)
SYTL4* 94121 28.0 15/18 (83%) THBS4 7060 2.9 8/18 (44%)
DUSP4 1846 14.7 14/18 (78%) AZGP1 563 2.8 9/18 (50%)
NAT1 9 11.7 15/18 (83%) BBC3* 27113 2.8 12/18 (67%)
ECM1* 1893 10.1 13/18 (72%) NET7* 23555 2.8 10/18 (55%)
KIAA0882 23158 10.1 18/18 (100%) NET6 27075 2.8 12/18 (67%)
JDP1 56521 10.0 12/18 (67%) TRAF5 7188 2.8 9/18 (50%)
ESR1 2099 9.8 18/18 (100%) BTG2 7832 2.7 9/18 (50%)
HDGFRP3 50810 9.8 12/18 (67%) RNF123* 63891 2.7 11/18 (61%)
TCEAL1 9338 9.8 13/18 (72%) CHAD* 1101 2.6 12/18 (67%)
TSPAN1* 10103 9.5 15/18 (83%) CSNK1A1 1452 2.6 14/18 (78%)
C20orf103* 24141 9.3 10/18 (55%) EVL 51466 2.6 12/18 (67%)
MYLIP 29116 9.3 11/18 (61%) HIST1H2BD 3017 2.6 10/18 (55%)
ABCA3 21 8.9 10/18 (55%) SUSD3 203328 2.6 9/18 (50%)
SEC14L2 23541 8.7 9/18 (50%) PLAT* 5327 2.6 8/18 (44%)
ANXA9* 8416 8.4 10/18 (55%) RARRES3* 5920 2.6 11/18 (61%)
KCTD3 51133 8.4 17/18 (94%) SH3BGRL* 6451 2.6 8/18 (44%)
SCUBE2 57758 7.5 14/18 (78%) TPBG* 7162 2.6 9/18 (50%)
ITGBL1 9358 7.1 8/18 (44%) UGCG 7357 2.6 11/18 (61%)
C14orf168 83544 6.7 6/18 (33%) CELSR2* 1952 2.5 8/18 (44%)
FBP1 2203 6.7 14/18 (78%) CRIM1 51232 2.5 11/18 (61%)
MYB 4602 6.7 14/18 (78%) FLJ90798* 219654 2.5 9/18 (50%)
RARA* 5914 6.7 12/18 (67%) KIF12 113220 2.5 7/18 (39%)
CaMKIINα 55450 6.3 18/18 (100%) LRIG1 26018 2.5 9/18 (50%)
AR* 367 6.2 10/18 (55%) LRP2* 4036 2.5 10/18 (55%)
ZNF552 79818 6.2 16/18 (89%) PHF15* 23338 2.5 12/18 (67%)
MIPEP* 4285 6.0 14/18 (78%) HSMNP1 55861 2.4 8/18 (44%)
BAI2 576 5.3 15/18 (83%) LOC123169 123169 2.4 12/18 (67%)
DP1L1 92840 5.3 15/18 (83%) PINK1* 65018 2.4 11/18 (61%)
VAV3 10451 5.3 12/18 (67%) PRKAR2B 5577 2.4 7/18 (39%)
KIAA0089 23171 5.2 17/18 (94%) TJP3* 27134 2.4 11/18 (61%)
GATA3 2625 5.1 15/18 (83%) CCND1 595 2.3 9/18 (50%)
QDPR 5860 5.1 11/18 (61%) CYBRD1 79901 2.3 10/18 (55%)
C1orf21 81563 4.9 11/18 (61%) KRT18 3875 2.3 10/18 (55%)
KIAA1143 57456 4.9 7/18 (39%) PURA 5813 2.3 9/18 (50%)
OIP106 22906 4.9 16/18 (89%) SREBF1* 6720 2.3 10/18 (55%)
AGR2 10551 4.6 10/18 (55%) CYB5R1 51706 2.2 6/18 (33%)
MGC4251 84336 4.6 13/18 (72%) DLG3* 1741 2.2 9/18 (50%)
FER1L3 26509 4.4 10/18 (55%) EEF1A2 1917 2.2 11/18 (61%)
C4A 720 4.1 11/18 (61%) GSTZ1 2954 2.2 9/18 (50%)
CRIP2 1397 4.0 15/18 (83%) LOC159090 159090 2.2 6/18 (33%)
NTN4 59277 4.0 10/18 (55%) MGC11242* 79170 2.2 10/18 (55%)
GJA1 2697 3.8 11/18 (61%) MGC18216* 145815 2.2 8/18 (44%)
CGI-111* 51015 3.7 14/18 (78%) NEIL1 79661 2.2 6/18 (33%)
CROT* 54677 3.6 15/18 (83%) XBP1* 7494 2.2 8/18 (44%)
DACH 1602 3.6 13/18 (72%) IRX5 10265 2.1 8/18 (44%)
DKFZP564D172 83989 3.6 10/18 (55%) RAB31 11031 2.1 9/18 (50%)
FGD3 89846 3.6 10/18 (55%) SSBP2 23635 2.1 7/18 (39%)
RNASE4* 6038 3.6 12/18 (67%) TGFB3 7043 2.1 8/18 (44%)
GLUL* 2752 3.3 11/18 (61%) BMPR1B 658 2.0 7/18 (39%)
FOXA1 3169 3.2 10/18 (55%) FLJ21174 79921 2.0 6/18 (33%)
MGC7036 196383 3.2 14/18 (78%) FLJ22386 79641 2.0 7/18 (39%)
MUC1* 4582 3.2 12/18 (67%) HSPB1* 3315 2.0 6/18 (33%)
NAV1 89796 3.1 13/18 (72%) IGFBP4* 3487 2.0 8/18 (44%)BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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other words, it appears that a better correlation was
observed between SAGE and oligonucleotide arrays, than
between both DNA microarray methods.
Conclusion
In summary, our comprehensive comparison of overlap-
ping genes across different gene expression platforms
provides validation for a significant number of transcripts
identified as highly expressed in ERα  (+) breast tumors.
More importantly this analysis identifies the most prom-
ising biomarkers for further evaluation as ERα  associated
genes in breast cancer. Furthermore, the identified pro-
teins may be of value as breast cancer prognostic indica-
tors analyzed either as a group or individually. It is also
likely that groups of co-regulated genes in ERα  (+) breast
cancers may be associated to the hormonal control of
mammary epithelial cells growth and differentiation.
Finally, a better understanding of the signaling networks
controlled or associated with the estrogen response may
lead to the identification of novel breast cancer therapeu-
tic targets.
Methods
SAGE libraries
To perform the comparative breast cancer SAGE analysis
based on ERα  status, we analyzed 26 Stage I – Stage II
invasive breast carcinomas (8 ERα -negative tumors and
18 ERα -positive tumors). To this end, we generated and
sequenced 24 breast cancer SAGE libraries at an approxi-
mate resolution of 100,000 tags per library, combined
with 2 additional breast cancer libraries (ERα -negative
tumors) downloaded from the Cancer Genome Anatomy
Project – SAGE Genie database
(SAGE_Breast_Carcinoma_B_95-259 and B_IDC_4)
http://cgap.nci.nih.gov/SAGE/. For the generation of our
SAGE libraries, snap frozen samples were obtained from
the M.D. Anderson breast cancer tumor bank, and SAGE
analysis was performed as previously described [36,38].
Data processing and statistical analysis of SAGE libraries
SAGE tag extraction from sequencing files was performed
by using the SAGE2000 software version 4.0 (a kind gift of
Dr. K. Kinzler, John Hopkins University). SAGE data man-
agement, tag to gene matching as well as additional gene
annotations and links to publicly available resources such
as GO, UniGene, LocusLink, were performed using a suite
of web-based SAGE library tools developed by us http://
spi.mdacc.tmc.edu/bitools/about/sage_lib_tool.html. In
our analyses we only considered tags with single tag-to-
gene reliable matches. To compare these SAGE libraries,
we utilized a modified t-test recently developed by us [18].
This test is based on a beta binomial sampling model that
takes into account both, the intra-library and the inter-
library variability, thus identifying 'common patterns' of
SAGE transcript tag changes systematically occurring
across samples [18].
All raw SAGE data reported as Supplementary tables in
this manuscript is publicly available at http://science
park.mdanderson.org/ggeg/sage_Proj_9.htm.
Real Time RT-PCR analysis
Template cDNAs were synthesized on mRNAs isolated
from an independent set of 36 Stage I – Stage II human
breast carcinomas (13 ERα -negative tumors and 23 ERα -
positive tumors) obtained from our tumor bank. Primers
and probes were obtained from the TaqMan Assays-on-
Demand™ Gene Expression Products (Applied Biosys-
tems, Foster City, CA, USA). All the PCR reactions were
performed using the TaqMan PCR Core Reagents kit and
the ABI Prism® 7700 Sequence Detection System (Applied
Biosystems, Foster City, CA, USA). Experiments were per-
formed in duplicate for each data point and 18s rRNA was
used as control. Results were expressed as mean ± 2 Stand-
ard Error based on Log2 transformation of normalized
real time RT-PCR values of the assayed genes. We used t-
test to compare the gene expression levels of validated
genes between ERα  (+) and ERα  (-) breast tumors (p <
0.05).
Immunohistochemical determination of ER status
IHC staining and ER status determination was performed
by the Pathology Department, MDACC following routine
immunohistochemical procedures. Briefly, five microme-
ter sections of invasive breast carcinomas paraffin embed-
ded tissues were used. Endogenous peroxidase activity
was blocked with 3% H2O2 in methanol for 10 min. After
pretreatment with Tris-EDTA buffer, in order to block
RPLP1* 6176 3.1 12/18 (67%) MGC15737* 85012 2.0 8/18 (44%)
ALCAM 214 2.9 9/18 (50%) SPARCL1 8404 2.0 9/18 (50%)
HSD17B4* 3295 2.9 13/18 (72%) STARD10* 10809 2.0 7/18 (39%)
* Genes with known or putative high-affinity EREs mapping in the vicinity of the TSS.
# Transcripts tags changing > 2-fold when compared with the average expression of ERα  (-) tumors. Underlined genes correspond to the 
transcripts cross-validated among all three compared platforms.
Table 2: Transcripts identified as over-expressed in ERα  (+) breast cancers commonly detected by cross-platforms comparison (SAGE 
and oligonucleotide microarrays). (Continued)BMC Genomics 2005, 6:37 http://www.biomedcentral.com/1471-2164/6/37
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non-specific antibody binding, the slides were incubated
with 10% goat serum in PBS for 30 min. Primary mono-
clonal ERα  antibody (ER-6F11, Novocastra, Newcastle,
UK) was used at 1:50 dilution and detected following
standard immunohistochemical techniques. DAB was
used as chromogen and Mayers hematoxylin is used as
counterstain. Scoring was performed by breast pathologist
(AS). Cuttoff for positivity was determined at 5% of tumor
cells staining positively for ER (i.e. < 5% of cells the tumor
was considered negative for ERα ).
Bioinformatics analysis
For automated functional annotation and classification of
genes of interest based on GO terms, we used the EASE
[31] available at the Database for Annotation, Visualization
and Integrated Discovery (DAVID) at http://
david.niaid.nih.gov/david[39]. The EASE software calcu-
lates over-representation of specific GO terms with respect
to the total number of genes assayed and annotated. Sta-
tistical measures of specific enrichment of GO terms are
determined by means of an EASE score (p < 0.05). The
EASE score is a conservative adjustment of the Fisher exact
probability that weights significance in favor of biological
themes supported by more genes and is calculated using
the Gaussian hypergeometric probability distribution that
describes sampling without replacement from a finite
population [31]. This allows one to identify biological
themes within a specific list of EASE analyzed genes.
High-affinity Estrogen Response Elements (ERE) analysis
To identify the occurrence of EREs within the promoter
regions of up-modulated genes in ERα  (+) breast tumors,
we used a human genome-wide high-affinity ERE data-
base http://mapageweb.umontreal.ca/maders/eredata
base/[32]. This public available database contains 71,119
EREs identified across the human genome (related to
17,353 transcriptional start sites), representing the con-
sensus ERE (5'-Pu-GGTCA-NNN-TGACC-Py-3'), and
equivalent sequences with only one or two nucleotide var-
iations from such consensus. Based on these restrictions
the expected random frequency was calculated as the total
number of base pairs in the human genome divided by
the frequency of occurrence of a sequence with specified
base pairs at 10 positions and two base pair choices at two
positions (3,069334246/411  = 732 high-affinity EREs)
[32].
Comparison of gene expression patterns identified by 
different methodologies
ERα  status associated genes identified in previous breast
cancer studies [12,13] using DNA microarray methods
were compared with our SAGE findings.
All over-expressed genes in ERα  (+) breast tumors
obtained from these studies were downloaded from the
corresponding web sites (http://www.nature.com/cgi-taf/
DynaPage.taf?file=/nature/journal/v415/n6871/abs/
415530a_fs.html and http://www.pnas.org/cgi/content/
abstract/100/18/10393) [12,13].
These datasets were annotated by LocusLink ID using the
EASE software [26], and then compiled into one Excel
spreadsheet pivotTable for comparison of overlapping
genes between platforms, i.e. SAGE, Oligonucleotide and
cDNA arrays. Anonymous ESTs from the microarrays plat-
forms were excluded due to the inability to cross validate
the identities between different gene expression profiles.
Any combination of two lists was compared for matching
gene-identity. The number and identity of genes com-
monly affected in two platforms (e.g. SAGE study vs. DNA
microarray) was determined. We used the normal approx-
imation to the binomial distribution as previously
described [40] to calculate whether the number of match-
ing genes derived from each cross-platform comparison
was of statistical significance (p < 0.05).
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